RECRUITING

Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Using a randomized controlled trial (RCT), the goal of this study is to evaluate the ability of evidence based behavioral treatment (contingency management: CM) to significantly decrease alcohol use and cigarette smoking among treatment-seeking smokers with an alcohol use disorder (AUD) who have initiated pharmacotherapy (varenicline; VC) for smoking cessation.

Official Title

Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking

Quick Facts

Study Start:2022-07-11
Study Completion:2026-05-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05181891

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. 4 or more standard drinks on the same occasion for women (5 or more standard drinks on the same occasion for men) on at least 4 occasions in the prior 30 days
  2. 2. Seeking AUD treatment
  3. 3. Seeking smoking cessation treatment
  4. 4. Aged 18+ years
  5. 5. DSM-5 diagnosis of AUD
  6. 6. Currently smoking daily according to PhenX Smoking Status (100 or more lifetime cigarettes plus current daily smoking)
  7. 7. Ability to read and speak English
  8. 8. Ability to provide written informed consent
  9. 9. Breath alcohol of 0.00 during informed consent
  10. 10. Provision of at least 1 EtG-positive urine test at any time during the induction period and at least one COT-positive urine test at any time during the induction period; and
  11. 11. Attended at least 4 of 6 possible visits during the induction period.
  1. 1. Significant risk of dangerous alcohol withdrawal, defined as a history of alcohol detoxification or seizure in the last 12 months and expression of concern by the participant about dangerous withdrawal
  2. 2. Currently receiving any pharmacotherapy for alcohol
  3. 3. Currently receiving any pharmacotherapy for smoking
  4. 4. No suicide attempt in the last 20 years and
  5. 5. Any other medical (discernable by initial blood tests) or psychiatric condition that Drs. Layton or Rodin determine would compromise safe participation.

Contacts and Locations

Study Contact

Abigail Bowen, MS
CONTACT
(425) 736-1354
abigail.bowen@wsu.edu
Sterling McPherson, PhD
CONTACT
(509) 324-7459
smcpherson05@wsu.edu

Principal Investigator

Sterling M McPherson, PhD
PRINCIPAL_INVESTIGATOR
Washington State University

Study Locations (Sites)

Washington State University
Spokane, Washington, 99202
United States

Collaborators and Investigators

Sponsor: Washington State University

  • Sterling M McPherson, PhD, PRINCIPAL_INVESTIGATOR, Washington State University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-07-11
Study Completion Date2026-05-01

Study Record Updates

Study Start Date2022-07-11
Study Completion Date2026-05-01

Terms related to this study

Keywords Provided by Researchers

  • Alcohol Use Disorder
  • Contingency Management
  • Incentives for Sobriety
  • Varenicline
  • Nicotine Use Disorder

Additional Relevant MeSH Terms

  • Alcohol Use Disorder (AUD)
  • Nicotine Use Disorder